Helicobacter pylori infection and extragastroduodenal diseases


Cite item

Full Text

Abstract

At present, the clinical significance of Helicobacter pylori infection has been validly determined within the development of a diversity of gastroduodenal diseases, including chronic gastritis, gastroduodenal ulcer, MALT lymphoma, and gastric adenocarcinoma. The Expert Council’s Maastricht IV consensus (2010) determining international standards for the diagnosis and treatment of H. pylori infection is that there is evidence that the latter may be associated with the development of a number of extragastroduodenal diseases (EGDDs) presented by iron-deficiency anemia of unspecified etiology, idiopathic thrombocytopenic purpura, and vitamin B12 deficiency. In these diseases, it is recommended that infection with H. pylori be diagnosed and, if the test is positive, this microorganism be eradicated. A large number of investigations have been recently conducted to examine the association of H. pylori infection with other EGDDs. This paper reviews theoretical and epidemiological data on the association of H. pylori with diseases of the cardiovascular (atherosclerosis, myocardial infarction) and central nervous (Alzheimer’s disease, Parkinson’s disease) systems, pancreas (autoimmune pancreatitis, pancreatic cancer), oncological (colonic adenomas, colorectal cancer, hepatocellular carcinoma), dermatological (chronic spontaneous urticaria), and other EGDDs. The review highlights the potential protective role of H. pylori in diseases with the atopic element of genesis and a complicated course of gastroesophageal reflux disease (Barrett’s esophagus, esophageal adenocarcinoma).

References

  1. Peura DA, Crowe SE. Helicobacter pylori. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010:chap 50.
  2. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010;15(Suppl 1):1-6. doi: 10.1111/j.1523-5378.2011.00874.x.
  3. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;8:4-12.
  4. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-638. doi: 10.1038/nrgastro.2014.99.
  5. Malfertheiner P, Megraud F, O’Morain C, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM , Kuipers EJ; European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(7):646-664. doi: 10.1136/gutjnl-2012-302084.
  6. Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20(36):12781-808. doi: 10.3748/wjg.v20.i36.12781
  7. Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2012;17(Suppl 1):49-55. doi: 10.1111/j.1523-5378.2012.00983.x.
  8. Шептулин А.А. Инфекция Helicobacter pylori: что еще кроме заболеваний желудка? Клиническая медицина. 2014;5:33-39.
  9. Hagymási K, Tulassay Z. Helicobacter pylori infection: new pathogenetic and clinical aspects. World J Gastroenterol. 2014;20(21):6386-6399. doi: 10.3748/wjg.v20.i21.6386.
  10. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008;13:323e40.
  11. Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, Lu LG, Sun X, Rong L, Zhong L, Sun DY, Lin H, Cai MC, Chen ZW, Hu B, Wu LM, Jiang YB, Yan WL. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010; 16:886e96.
  12. Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Effect of Helicobacter pylori eradication on iron deficiency. Chin Med J (Engl). 2010;123:1924-1930.
  13. Yokota S, Toita N, Yamamoto S, Fujii N, Konno M. Positive relationship between a polymorphism in Helicobacter pylori neutrophil-activating protein a gene and iron-deficiency anemia. Helicobacter. 2013;18:112-116. doi: 10.1111/hel.12011.
  14. Franchini M, Veneri D. Helicobacter pylori-associated immune thrombocytopenia. Platelets. 2006;17:71-77.
  15. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, Crowther MA. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009;94:850e6. doi: 10.3324/haematol.2008.005348.
  16. Yu T, Wu D, Zhao XY. Infection and eradication of Helicobacter Pylorus affecting etiology and curative effect of idiopathic thrombocytopenic purpura: a META analysis. Zhongguo Shiyanxue Yexue Zazhi. 2011;19:1255-1259.
  17. Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol. 2012; 24:429-434.
  18. Lahner E, Persechino S, Annibale B. Micronutrients (Other than iron) and Helicobacter pylori infection: a systematic review. Helicobacter. 2012;17:1-15.
  19. Vitale G, Barbaro F, Ianiro G, Cesario V, Gasbarrini G, Franceschi F, Gasbarrini A. Nutritional aspects of Helicobacter pylori infection. MinervaGastroenterol Dietol. 2011;57(4):369-377.
  20. Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16:124-130. doi: 10.1111/j.1523-5378.2011.00830.x.
  21. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66:1824-1829.
  22. Hashim H, Azmin S, Razlan H., Yahya NW, Tan HJ, Manaf MR, Ibrahim NM. Eradication of Helicobacter pylori Infection Improves Levodopa Action, Clinical Symptoms and Quality of Life in Patients with Parkinson’s Disease. PLoS One. 2014;9(11):e112330. doi: 10.1371/journal.pone.0112330. ecollection 2014.
  23. Al-Ghamdi A, Jiman-Fatani AA, El-Banna H. Role of Chlamydia pneumoniae, helicobacter pylori and cytomegalovirus in coronary artery disease. Pak J Pharm Sci. 2011;24(2):95-101.
  24. Jafarzadeh A, Nemati M, Tahmasbi M, Ahmadi P, Rezayati MT, Sayadi AR. The association between infection burden in Iranian patients with acute myocardial infarction and unstable angina. Acta Med Indones. 2011;43(2):105-111.
  25. Franceschi F, Brisinda D, Buccelletti F, Ruggieri MP, Gasbarrini A, Sorbo A, Marsiliani D, Venuti A, Fenici P, Gasbarrini G, Silveri NG, Fenici R. Prevalence of virulent Helicobacter pylori strains in patients affected by idiopathic dysrhythmias. Intern Emerg Med. 2013;8(4):333-337. doi: 10.1007/s11739-011-0621-8.
  26. Padmavati S, Gupta U, Agarwal HK. Chronic infections & coronary artery disease with special reference to Chalmydia pneumonia. Indian JMed Res. 2012;135:228-232.
  27. Liu J, Wang F, Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants. Helicobacter. 2014. doi: 10.1111/hel.12188. [epub ahead of print]
  28. He C, Yang Z, Lu NH. Helicobacter pylori-An Infectious Risk Factor for Atherosclerosis? J Atheroscler Thromb. 2014;21(12):1229-1242.
  29. Kountouras J, Zavos C, Deretzi G, Gavalas E, Polyzos S, Vardaka E, Kountouras C, Giartza-Taxidou E, Koutlas E, Tsiptsios I. Helicobacter pylori may play an important role in both axonal type Guillain-Barré syndrome and acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurol Neurosurg. 2011;113(6):520. doi: 10.1016/j.clineuro.2011.01.004.
  30. Kountouras J, Boziki M, Zavos C, Gavalas E, Giartza-Taxidou E, Venizelos I, Deretzi G, Grigoriadis N, Tsiaousi E, Vardaka E. A potential impact of chronic Helicobacter pylori infection on Alzheimer’s disease pathobiology and course. Neurobiol Aging. 2012;33(7):e3-4. doi: 10.1016/j.neurobiolaging.2012.01.003.
  31. Yin P, Yang L, Zhou HY, et al. Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy. Med Hypotheses. 2011;76(2):184-186. doi: 10.1016/j.mehy.2010.09.013.
  32. Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, Tzilves D, Katsinelos P, Tsolaki M, Chatzopoulos D, Venizelos I. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer’s disease. J Neurol. 2009;256:758-767. doi: 10.1007/s00415-009-5011-z.
  33. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Chatzigeorgiou S, Katsinelos P, Grigoriadis N, Giartza-Taxidou E, Venizelos I. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol. 2010;23:199-204. doi: 10.1097/wnn.0b013e3181df3034.
  34. Wu Q, Yang ZP, Xu P, Gao LC, Fan DM. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Dis. 2013;15(7):e352-е364. doi: 10.1111/codi.12284.
  35. Wang F, Sun MY, Shi SL, Lv ZS. Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case-control studies. Colorectal Dis. 2014;16(4):246-252. doi: 10.1111/codi.12290.
  36. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol. 2013;108:208-215. doi: 10.1038/ajg.2012.407.
  37. Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Battett’s and colorectal carcinogenesis. World J Gastroenterol. 2012;18:6560-6570. doi: 10.3748/wjg.v18.i45.6560.
  38. Rabelo-Gonçalves EM, Sgardioli IC, Lopes-Cendes I, Escanhoela CA, Almeida JR, Zeitune JM. Improved detection of Helicobacter pylori DNA in formalin-fixed paraffin-embedded (FFPE) tissue of patients with hepatocellular carcinoma using laser capture microdissection (LCM). Helicobacter. 2013;18:244-245. doi: 10.1111/hel.12040.
  39. Tu QV, Okoli AS, Kovach Z, Mendz GL. Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. Future Microbiol. 2009;4:1283-1301. doi: 10.2217/fmb.09.90.
  40. Xuan SY, Xin YN, Chen AJ, Dong QJ, Qiang X, Li N, Zheng MH, Guan HS. Association between the presence of H. pylori in the liver and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2008;14:307-312. doi: 10.3748/wjg.14.307.
  41. Jaworek J, Bilski J, Jachimczak B, Cieszkowski M, Kot M, Bielanski W, Konturek SJ. The effects of ammonia on pancreatic enzyme secretion in vivo and in vitro. J Physiol Pharmacol. 2000;51:315-332.
  42. Hori Y, Takeyama Y, Shinkai M, Ueda T, Yamamoto M, Sugiyama T, Kuroda Y. Inhibitory effect of vacuolating toxin of Helicobacter pylori on enzyme secretion from rat pancreatic acini. Pancreas. 1999;18:324-327.
  43. Кучерявый Ю.А. Инфекция Helicobacter pylori и заболевания поджелудочной железы. Клиническая фармакология и терапия. 2004;13(1):40-43.
  44. Кучерявый Ю.А. Хронический панкреатит как кислотозависимое заболевание. Экспериментальная и клиническая гастроэнтерология. 2010;9:107-115.
  45. Domínguez-Muñoz JE, Malfertheiner P. Effect of Helicobacter pylori infection on gastrointestinal motility, pancreatic secretion and hormone release in asymptomatic humans. Scand J Gastroenterol. 2001;36:1141-1147.
  46. Dore MP, Sepulveda AR, Pedroni A, Realdi G, Delitala G. Reversal of elevated pancreatic enzymes after Helicobacter pylori eradication. InternEmerg Med. 2008;3(3):269-270. doi: 10.1007/s11739-008-0117-3.
  47. Bulajic M, Panic N, Löhr JM. Helicobacter pylori and pancreatic diseases. World J Gastrointest Pathophysiol. 2014;5(4):380-383. doi: 10.4291/wjgp.v5.i4.380.
  48. Маев И.В., Кучерявый Ю.А., Оганесян Т.С. Аутоиммунный панкреатит. Учебное пособие для врачей. М.: ФГУ «ФИРО» Минобрнауки РФ; 2011.
  49. Guarneri F, Guarneri C, Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry? J Cell Mol Med. 2005;9:741-744.
  50. Frulloni L, Lunardi C, Simone R, Dolcino M, Scattolini C, Falconi M, Benini L, Vantini I, Corrocher R, Puccetti A. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med. 2009;361:2135-2142. doi: 10.1056/nejmoa0903068.
  51. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D; ATBC Study. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst. 2001;93(12):937-941.
  52. Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, Hejna M, Scheithauer W. Association between Helicobacter pylori infection and pancreatic cancer. Oncology. 1998;55(1):16-19.
  53. Trikudanathan G, Philip A, Dasanu CA, Baker WL. Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP. 2011;12(1):26-31.
  54. Xiao M, Wang Y, Gao Y. Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS One. 2013;8(9):e75559. doi: 10.1371/journal.pone.0075559.
  55. Nilsson HO, Stenram U, Ihse I, Wadstrom T. Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J Gastroenterol. 2006;12:3038-3043.
  56. Chiu YC, Tai WC, Chuah SK, Ping-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chao-Cheng Huang, Ji-Chen Ho, Johannes Ring, and Wen-Chieh Chen. The Clinical Correlations of Helicobacter pylori Virulence Factors and Chronic Spontaneous Urticaria. Gastroenterol Res Pract. 2013;2013:436727.
  57. Argenziano G, Donnarumma G, Iovene MR, Arnese P, Baldassarre MA, Baroni A. Incidence of anti-Helicobacter pylori and anti-CagA antibodies in rosacea patients. Int J Dermatol. 2003;42:601-604.
  58. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol. 2009;19:431-444.
  59. Onsun N, Arda Ulusal H, Su O, Beycan I, Biyik Ozkaya D, Senocak M. Impact of Helicobacter pylori infection on severity of psoriasis and response to treatment. Eur J Dermatol. 2012;22(1):117-120. doi: 10.1684/ejd.2011.1579.
  60. Xiong LJ, Tong Y, Wang ZL, Mao M. Is Helicobacter pylori infection associated with Henoch-Schonlein purpura in Chinese children? A meta-analysis. World J Pediatr. 2012;8:301-308. doi: 10.1007/s12519-012-0373-1.
  61. Li Q, Lin X, Wu Z, He L, Wang W, Cao Q, Zhang J. Immuno-histochemistry analysis of Helicobacter pylori antigen in renal biopsy specimens from patients with glomerulonephritis. Saudi J Kidney DisTranspl. 2013;24:751-758.
  62. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2011;16(Suppl 1):65-69. doi: 10.1111/j.1523-5378.2011.00883.x.
  63. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systemic review. Helicobacter. 2011;16:79-88. doi: 10.1111/j.1523-5378.2011.00822.x.
  64. Cardaropoli S, Rolfo A, Piazzese A, Ponzetto A, Todros T. Helicobacter pylori’s virulence and infection persistence define pre-eclampsia complicated by fetal growth retardation. World J Gastroenterol. 2011;17(47):5156-5165. doi: 10.3748/wjg.v17.i47.5156.
  65. Franceschi F, Di Simone N, D’Ippolito S, Castellani R, Di Nicuolo F, Gasbarrini G, Yamaoka Y, Todros T, Scambia G, Gasbarrini A. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia? Helicobacter. 2012;17(6):426-434. doi: 10.1111/j.1523-5378.2012.00966.x.
  66. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149-1158. doi: 10.1002/cncr.27834
  67. Cullen D, Hawkey G, Greenwood D. H. pylori and gastroesophageal reflux disease: a community-based study. Helicobacter. 2008;13:352e60.
  68. O’Connor HJ. Review article: helicobacter pylori and gastroesophageal reflux disease-clinical implications and management. Aliment PharmacolTher. 1999;13:117e27.
  69. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5:1413e17,1417.
  70. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, Shao L, Zou DH, Yu XM, Mao WM. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19:6098-6107. doi: 10.3748/wjg.v19.i36.6098.
  71. Rodrigues Jr L, Faria CM, Geocze S, Chehter L. Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial. Arq Gastroenterol. 2012;49:56-63.
  72. Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195-205. doi: 10.1097/meg.0b013e328363e2c7.
  73. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, Müller A. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest. 2011;121(8):3088-3093. doi: 10.1172/jci45041.
  74. Serrano CA, Talesnik E, Peña A, Rollán A, Duarte I, Torres J, Majerson D, Einisman H, Viviani P, Harris PR. Inverse correlation between allergy markers and Helicobacter pylori infection in children is associated with elevated levels of TGF-β. Eur J Gastroenterol Hepatol. 2011;23(8):656-663. doi: 10.1097/meg.0b013e328347c231.
  75. Wang Y, Bi Y, Zhang L, Wang C. Is Helicobacter pylori infection associated with asthma risk? A meta-analysis based on 770 cases and 785 controls. Int J Med Sci. 2012;9(7):603-610.
  76. Wang Q, Yu C, Sun Y. The association between asthma and Helicobacter pylori: a meta-analysis. Helicobacter. 2013;18(1):41-53. doi: 10.1111/hel.12012.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies